Translate:
Dr. Ari D. Baron
CURRENT TITLE
Hematologist-Oncologist
Pacific Hematology-Oncology Associates
California Pacific Medical Center
San Francisco, CA
September 1996 - Present
Chairman, Science Committee
Sutter Cancer Research Group
2001 - Present
Associate Clinical Professor
Department of Medicine, University of California
San Francisco, CA
June 2004 - Present
Medical Director
Clinical Oncology Research Program
California Pacific Medical Center
San Francisco, CA
December 2007 - Present
Chief, Division of Hematology -Oncology
California Pacific Medical Center
San Francisco, CA
December 2012 - Present
Associate Clinical Professor
Department of Medicine
Geisel School of Medicine
Hanover, NH
July 2014 - Present
Governing Member
SWOG Board of Governors
October 2015 - Present
EDUCATION
Wesleyan University
Middletown, CT
B.A. in English, May 1984
Tufts University School of Medicine
Boston, MA, M.D., May 1990
University of California, San Francisco, Department of Medicine
San Francisco, CA
Medical Residency, June 1993
University of California, San Francisco, Division of Hematology-Oncology
San Francisco, CA
Hematology-Oncology Fellowship
July 1994 - September 1996
University of California, San Francisco, Department of Epidemiology and Biostatistics.
San Francisco, CA
Outcomes Research and Clinical Epidemiology
August, 1996
LICENSES AND CERTIFICATIONS
California Medical license: G072619 since October 1991
Diplomate, American Board of Internal Medicine
September 1993
Diplomate, ABIM: Medical Oncology
November 1997, 2007
PRINCIPLE POSITIONS HELD
Staff Physician
Veterans Administration Medical Center
San Francisco, CA
July 1993 - July 1994
Staff Physician
San Francisco General Hospital Emergency Services
San Francisco, CA
July 1993 - July 1996
Clinical Instructor
Department of Medicine, UCSF
San Francisco, CA
July 1993 - June 1994 & July 1995 – June 1997
Assistant Clinical Professor
Department of Medicine, UCSF
San Francisco, CA
June 1997 – June 2004
Clinical Associate
Department of Epidemiology & Biostatistics, UCSF
San Francisco, CA
July 1995 – June 1996
HONORS AND AWARDS
Joseph Collins Foundation Grant, based on academic achievement and demonstrated interest in the arts and letters, 1988 - 1990
Alpha Omega Alpha, National Medical Honors Society, October 1989.
Julius Krevans Award for clinical excellence, Department of Medicine.
UCSF, April 1991. Awarded to outstanding intern.
Excellence in Teaching Award, Department of Medicine. Awarded to outstanding teacher among clinical fellows by medicine house staff.
UCSF, 1995.
PROFESSIONAL AFFILIATION
Massachusetts Medical Society
1986 - Present
San Francisco Interns and Residents Association
1990 - 1993
American College of Physicians
1993 - Present
San Francisco Medical Society
September 1996 - Present
American Society of Clinical Oncology
Active Member
July, 1996 - Present
UNIVERSITY SERVICE
Interdepartmental Task Force to establish disability insurance coverage for house staff.
UCSF Medical Center, 1991
Fellowship education committee, established to review and redesign training program. Division of Hematology-Oncology
UCSF, Fall 1995
Interviewer, Internal Medicine Residing Program, California Pacific Medical Center
UCSF, 1998 – 2002
Anticoagulation Quality Assurance: Developed guidelines and teaching tools to improve safety of anticoagulation.
California Pacific Medical Center, San Francisco, 1997-1998
Chairman, Science Committee, California Pacific Medical Center, San Francisco, CA. Develop and administer clinical research program in oncology for largest private hospital in Northern California.
2001-present
COMMUNITY SERVICE
Co-founder, Student, Student Committee on Racial Awareness, Wesleyan University, Middletown, CT.
Developed and led workshops on racism on campus.
1981 - 1984
Co-founder, AIDS Education Group, Tufts University School of Medicine, Boston, MA. Developed and led
workshops on AIDS education for resident advisors, Tufts undergraduate campus.
Fall 1986
Co-founder Member, Kids in Chemotherapy Support. Helped start group of Big Brothers and Sisters to support children with cancer. New England Medical Center, Boston Floating Hospital for Children.
1987 - 1989
Member, Board of Directors, Patient Assistance Foundation.
California Pacific Medical Center, San Francisco, CA
June, 2007 - Present
Member, Board of Directors, Developing Indigenous Resources, a non-profit organization committed to health care in India.
June, 2007
Chairman, Board of Directors, Patient Assistance Foundation.
California Pacific Medical Center, San Francisco, CA
2010 - 2013
RESEARCH EXPERIENCE
Research Technician, Division of Cell Biopsy, Children’s Hospital, Boston, MA. Independently involved in the investigation of the structure and regulation of the acute phase response genes of the human immune system.
1984 - 1986
Clinical Research Intern, Division of Adult Oncology, Hammersmith Hospital, London. Followed patients in Phase II clinical trial of radiolabeled monoclonal antibodies against ovarian cancer.
Summer 1986
PUBLICATIONS
ABSTRACTS:
GENITOURINAR Y MALIGNANCIES.
1. Small E.S., Baron A.D., Bok R. "Simultaneous Anti-Androgen Withdrawal and Treatment with Ketoconazole in Patients with Advanced Hormone Refractory Prostate Cancer." Proc ASCO Abstract #1117, 1996.
2. Hussain, DiPaola, Baron, Higano, Tchekmedyian, Miller, Rothermel. "Phase Il Trial of Weekly Patupilone (EPO 906) in Patients with Castration-Resistant Prostate Cancer." Proc ASCO, 2004; Abstract #4563.
3. Danila DC, Szmulewitz RZ, Baron A, Higano CS, Scher HI, Morris M, Gilbert H, Brunstein F, Lemahieu V, Kabbarah O, Fine BM Maslyar DJ, Vasihampayan, U. Abstract Title: A Phase I Study ofDSTP3086S, an Antibody-Drug Conjugate Targeting STEAPI, in Patients with Metastatic Castration-Resistant Prostate Cancer, Proc ASCO, 2014, abstract #5024.
4. Andrea Necchi, Marc-Oliver Grimm, Margitta Retz, Jose Angel Arranz Arija, Sergio Bracarda, Jens Bedke, Ari David Baron, Padmanee Sharma, Matt D. Galsky, Daniel A. Vaena, Ewa Kalinka-Warzocha, Magdalena Cwikiel, Sumanta K. Pal, Rafael Morales, Fiona Taylor, Kyna McCullough Gooden, Elizabeth R. Plimack. Abstract Title: Health-related quality of lift) as a marker of treatment benefit with nivolumab in platinum-refractory patients with metastatic or unresectable urothelial carcinoma from CheckMate 275. Proc ASCO, June 2017, Abstract #189329.
GASTROINTESTINAL MALIGNANCIES:
1. Koch, Baron, Roberts, Junker, Palacay-Ramona, Masson, Laurent, Kay, Wiedenmann, Cebon. "Influence of Hepatic Dysfunction on Safety, Tolerability and Pharmacokinetics of PTK787/ZK 222584 in Patients with Unresectable Hepatocellular Carcinoma." Proc ASCO, 2005; Abstract #4134.
2. A. Parthasarathy, D.L. Glaubiger, K. M. Grant, A.D. Baron, California Pacific Medical Center, San Francisco, CA, Abstract Title: Treatment of anal carcinoma in HIV-positive males: A single institution experience, Proc ASCO/GI, 2008, abstract #340.
3. Y.Z. Patt, A.D. Baron, V. A. Parks, A. Small, M. Roach, S. Lee, F. Lee. Abstract Title: Phase Il trial of gemcitabine (G), oxaliplatin (O), an erlotinib (T) for the treatment of hepatocellular carcinoma (HCC)and biliary tree cancers (BTC), Proc ASCO, 2010, abstract #4153.
4. Ari D Baron, Cindy L O'Bryant, Younjeong Choi, Avi Ashkenazi, Stephanie Royer-Joo, Chia C Portera. Abstract Title: Phase 1b Study of Drozitumab Combined with Cetuximab (CET) + Irinotecan (IRI) or with FOLFIRI + Bevacizumab (B V) in Previously Treated Patients (patient's) with Metastatic Colorectal Cancer (mCRC), Proc ASCO, 2011, abstract #3581.
5. A Zhu, B-Y. Ryoo, C-J. Yen, M Kudo, R. Poon, D. Pastorelli, J-F. Blanc, H. Chung, A. Baron, T. Pfiffer, T. Okusaka, K. Kubackova, J. Trojan, J. Sastre, I, Chau, S-C. Chang, P. Abada, L. Yang, J. Schwartz, J. Park. Abstract Title: Ramuciumab (RAM; IMC-1121B) as Second-Line Treatment in Patients with Advanced Hepatocellular Carcinoma Following First-Line Therapy with Sorafenib: Results from the Randomized Phase Ill REACH Study, Proc ESMO, October 2014.
6. Ghassan K Abou-Alfa, Rebecca A. Miksad, Martin E. Gutierrez, Mohamedtaki A. Tejani, Manish R. Sharma, Weijing Sun, Charles A. Henderson, Ari D. Baron, Olugbenga O. Olowokure, R. Scott Pearsall, Dawn M. Wilson, Chris Korth, Matthew L. Sherman, Shuchi S. Pandya. Abstract Title: The DASH Study: A Phase 1b Study of Dalantercept Plus Sorafenib in Advanced Hepatocellular Carcinoma, Proc ASCO/GI, January 2015, abstract #TPS495.
7. Thomas, MB, Garrett-Mayer, E, Anis, M, Anderton, K, Bentz, T, Adelman, A, Brisendine, A, Duddalwar, V, Weiss, G, Siegel, AB, Bendell, J, Baron, A, El-Khoueiry, A. Abstract Title: A Randomized Open Label Multi-Institution Phase Il Study of the Combination of Bevacizumab (B) and Erlotinib (E) Compared to Sorafenib (S) in the First-Line Treatment of Patients (patient's) with Advanced Hepatocellular Carcinoma(HCC), Proc ASCO /GI, 2015, abstract #337.
8. Andrew X. Zhu, Baek-Yeol Ryoo, Chia-Jui Yen, Masatoshi Kudo, Ronnie Poon, Davide Pastorelli, Jean-Frederic Blanc, Hyun Cheol Chung, Ari D. Baron, Tulio IEduardo Flesch Pfiffer, Takuji Okusaka, Katerina Kubackova, Jorg Trojan, Javier Sastre, Ian Chau, Shao-Chun Chang, Paolo B. Abada, Ling Yang, Yanzhi Hsu, Joon Oh Park. Abstract Title: Ramucirumab as Second-Line Treatment in Patients with Advanced Hepatocellular Carcinoma: Analysis of Patients with Elevated a-Fetoprotein from the Randomized Phase Ill REACH Study, Proc ASCO/GI, January 2015, abstract #232.
9. Ian Chau, Ari David Baron, Peter Malfertheiner, Masatoshi Kudo, Seiji Kawazoe, Denis Pezet, Florian Weissinger, Giovanni Brandi, Carlo Barone, Takuji Okusaka, Yoshiyuki Wada, Joon Oh Park, Baek-Yeol Ryoo, Jae Yong Cho, Hyun Cheol Chung, Chung-Pin Li, Chia-Jui Yen, Kuan-Der Lee, Ling Yang, Andrew X. Zhu. Abstract Title: Ramucirumab(RAM) as Second-Line Treatment in Patients with Advanced Hepatocellular Carcinoma (HCC); Analysis of Patient's by Child-Pugh Score, oral abstract Proc ASCO, May 2015.
10. Markus Moehler, Han Chu Lee, Won Young Tak, Yee Chao, Seung Woon Paik, Ari Baron, Guy Ugerechts, Jean-Frederic Blanc, Mong Cho, Laura Findeiss, Francois Habersetzer, Derek Jonker, Philippe Merle, Leyo Ruo, Oliver Ebert, Tony Reid, Riccardo Lencioni, Adina Pelusio, Monika Lusky, Nicolas Stojkowitz, Marie Hennequi, David H. Kirn, Jean-Marc Limacher, Caroline J. Breitbach, Michael Homerin, James Burke, Jeong Heo. Abstract Title: Randomized Phase 11b study ofPexa-Vec (pexastimogene devacirepvec JX-594), an oncolytic immunotherapy plus best supportive care (BSC) versus BSC alone in patients with hepatocellular carcinoma (HCC) who failed sorafenib treatment (TRAVERSE); Proc ILCA, September 2015.
I l . Ian Chau, Markus Peck-Radosavljevic, Christophe Borg, Peter Malfertheiner, Jean Francois Seitz, Jooh Oh Park, Baek-Yeol Ryoo, Chia-Jui Yen, Masatoshi Kudo, Ronnie Poon, Davide Pastorelli, Jean-Frederic Blanc, Hyun Cheol Chung, Ari D. Baron, Tajuji Okusaka, Zhanglin Lin Cui, Allicia C. Girvan, Paolo B. Abada, Ling Yang, Andrew X. Zhu; Oral Abstract Title: Ramucirumab (RAM) as Second-Line Treatment in Patients with Advanced Hepatocellular Carcinoma following First-Line Therapy with Sorafenib: Patient-Focused Outcome (PFO) Results from the Randomized Phase 3 REACH Study; Proc ASCO, May 2015.
12. Sunil R. Hingorani, William P. Harris, Tara Seery, Lei Zheng, Darren Sigal, Andrew Hendifar, Fai Braiteh, Mark
Zalupski, Ari Baron, Nathan Bahary, Andrea Wang-Gillam, Noelle LoConte, Gregory Springett, Paul Ritch, Aram Hezel, Wen Wee Ma, Venu Bathini, Wilson Wu, Ping Jiang, Andrea Bullock. Abstract Title: Interim results of a randomized phase 2 study of PEGPH20 added to nab-paclitaxel/gemcitabine in patients with stage IV previously untreated pancreatic cancer; Proc ASCO/GI, January 2016.
13. Jean-Frederic Blanc, Stephen Chan, Joon Oh Park, Baek-Yeol Ryoo, Chia-Jui Yen O, Masatoshi Kudo, Ronnie Poon, Davide Pastorelli, Ari Baron, Tulio Felsch Pfiffer, Takuji Okusaka, Katerina Kubackova, Jorg Trogan, Javier Sastre, Ian Chau, Paolo Abada, Shao-Chun Chang, Ling Yang, Andrew Zhu; Abstract Title: Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HOC): Analysis of REACH patients by Albumin-Bilirubin (ALBI) grade; presentation at EASL-International Liver Congress Meeting, April 2016.
14. Richard Kim, Shannon McDonough, Anthony El-Khoueiry, Tanios Bekaii-Saab, Stacey Stein, Vaibhav Sahai, George P. Keogh, Edward J. Kim, Ari D. Baron, Abby B. Siegel, Afsaneh Barzi, Katherine A. Guthrie, Milind Javle, Howard Hochster. SWOGS1310: Randomized Phase Il Trial of Single Agent MEK 'Inhibitor Trametinib vs. 5-Fluorouracil or Capecitabine in Refractory Biliary Cancer. Proc ASCO, June 2017.
15. Ann-Lii Cheng, Richard S. Finn, Shukui Qui, Kwang-Hyub Han, Kenji Ikeda, Fabio Piscaglia, Ari David Baron, Joong-Won Park, Guohong Han, Jacek Jassem, Jean-Frédéric Blanc, Arndt Vogel, Dmitry Komov, T.R. Jeffry Evans, Carlos L6pez-L6pez, Corina E. Dutcus, Min Ren, Silvija Kraljevic, Toshiyuki Tamai, Masatoshi Kudo. Abstract Title: Phase 3 trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC). Proc ASCO, June 2017, abstract #186143.
16. R. S. Finn, M. Kudo, A.-L. Chen, L. Wyrwicz, R. Ngan, J.-F. Blanc, A. D. Baron, A. Vogel, M. Ikeda, F. Piscaglia, K.-H. Han, S. Qin, Y, Minoshima, Y. Funahaski, M. Ren, R. Dairiki, P. Sachdev, T, Tamai, C. Dutcus, T.R.J. Evans; Title: Analysis of Serum Biomarkers in Patients from a Phase 3 Study of Levatinib vs. Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma; European Society for Medical Oncolgy (ESMO) Congress, September 2017.
OTHER:
l . Burstein H., Keshaviah A., Baron A., Hart R. , Lambert-Falls R., Marcom Pa, Gelman R., Winer E. "Trastuzumab and Vinorelbine or Taxane Chemotherapy for HER-2+ Metastatic Breast Cancer: The TRAVIOTA Study." Proc 
ASCO, 2006; Abstract #650.
2. J.L. Wade, Shaker Dakhil, Ari Baron, Sylvie Rottie, IFredrick Millard, Daugaard Gedske, Jean-Pascale Machiels, William Conkright, Sunile Shanna, Patricial Soetekouw, Jeffrey Yachning, Lisa Sengelove, Peter Van Veldhuizen, Sanjiv Agarwala, Quyen Nguyen, Mustapha Chadjaa, Pierre Maison-Blanche, Abstract Title: A QTc study of cabazitaxel in patients with advanced solid tumors, Proc ASCO/GU, 20.
3. Elizabeth MH Kim, Lea Ann Bernick, Stacy D' Andre, Eunpi Cho, Peter Yu, Christopher Jones, Ari Baron, Milana Dolezal, Stephanie Jeske, John Chan, Alex Garcia-young, Michael Rowbotham. Poster Presentation: Strategic Implementation of Cancer Research Model In a Community Based Health Care System. National Consortium of Breast Centers Meeting. March 2017.
ARTICLES:
GENITOURINARY MALIGNANCIES:
1. Small E.J., Baron A.D., Flippin L. "Ketoconazole Retains Activity in Advanced Prostate Cancer Patients Who Have Progressed Despite Flutamide Withdrawal." Journal of Urology, 1997; 157:1207-1207.
2. Small E.S., Baron A.D., Bok R. "Simultaneous Anti-Androgen Withdrawal and Treatment with Ketoconazole in Patients with Advanced Hormone Refractory Prostate Cancer." Cancer, 1997; 80:1755-1759.
3. Hussain, DiPaola, Baron, Higano, Tchekmedyian, Miller, Rothermel. "Phase Il Trial of Weekly Patupilone (EPO 906) in Patients with Castration-Resistant Prostate Cancer." Annals of Oncology,
4. Padmanee Sharma, Margitta Retz, Arlene Siefker-Radtke, Ari Baron, Andrea Necchi, Jens Bedke, Elizabeth R. Plimack, Daniel Vaena, Marc-Oliver Grimm, Sergio Bracarda, José Angel Arranz, Sumanta Pal, Chikara Ohyama, Abdel Saci, Xiaotao Qu, Alexandre Lambert, Suba Krishnan, Alex Azrilevich, Matthew D. Galsky; "Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial." The Lancet Oncology, March 2017; 18:312-322.
GASTROINTESTINAL MALIGNANCIES:
l . Hurwitz, Fehrenbacher, Novotny, Cartwright, Hainsworth, Heim, Berlin, Baron, Griffing, Holmgren, Ferrara, Fyfe, Rogers, Ross, Kabbinnavar. "Addition of Bevacizumab (rhuMab VEGF) to Bolus IFL in the First-Line Treatment of Patients with Metastatic Colorectal Cancer: Results of a Randomized Phase Ill Trial. New England Journal ofMedicine,
2. Gish R. and Baron A. "Hepatocellular Carcinoma: Current and Evolving Therapies". IDrugs, 2008; 1 1 198-203.
3. Andrew X. Zhu, Joon Oh Park, Baek-Yeol Ryoo, Chia-Jui Yen, Ronnie Poon, Davide Pastorelli, Jean-Frederic lanc, Hyun Cheol Chung, Ari D. Baron, Tulio Edurdo Flesch Pfiffer, Takuji Okusaka, Katerina Kubackova, Jorg Trojan, Javier Sastre, Ian Chau, Shao-Chun Chang, Paolo B. Abada, Ling Yang, Jonathan D. Schwartz, Masatoshi Kudo; "Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial REACH Study." The Lancet Oncolou, July 2015; 66:859-870.
4. Andrew X. Zhu, Ari David Baron, Peter Malfertheiner, Masatoshi, Seiji Kawazoe, Denis Pezet, Florian Weissinger, Giovanni Brandi, Carlo A. Baron, Takuji Okusaka, Yoshiyuki Wada, Joon Oh Park, Baek-Yeol Ryoo, Jae Yong Cho, Hyun Cheol Chung, Chung-Pin Li, Chia-Jui Yen, Kuan-Der Lee, Shao-Chun Chang, Ling Yang, Paolo B. Abada, Ian Chau; "Ramucirumab as Second-Line Treatment in Patients with Advanced Hepatocellular Carcinoma; Analysis of REACH Trial Results by Child-Pugh Score." JAMA Oncology, 
Doi: 10.1001/jamaoncol.2016.4115.
5. Ian Chau, Markus Peck-Radosavljevic, Christopher Borg, Peter Malfertheiner, Jean Francois Seitz, Joon Oh Park, Baek-Yeol Ryoo, Chia-Jui Yen, Masatoshi Kudo, Ronnie Poon, Davide Pastorelli, Jean-Frederic Blanc, Hyun Cheol Chung, Ari D. Baron, Takuji Okusaka, L. Bowman, Zhanglin Lin Cui, Allicia C. Girvan, Paolo B. Abada, Ling Yang, Andrew X. Zhu; "Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma föllowing first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase Ill REACH study." European Journal ofCancer, August 2017;vol 81 :17-25.
6. Yehuda Z. Patt, Waheed Murad, Mohammed H. Fedrazad, Ari D. Baron, Pranshu Bansal, Yanis Boumber, Kin Steinberg, Sang-Joon Lee, Ed Bedrick, Rofä Du, Fa, Chyi Lee; INST OX-05-024: First line gemcitabine, oxaliplatin, and erlotinib for primary hepatocellular carcinoma and bile duct cancers; a multicenter Phase Il trial; Cancer Medicine, June 2017.
7. D. Arnold, C. S. Fuchs, J. Tabernero, A. Ohtsu, A. X. Zhu, E. B. Garon, J. R. Mackey, L. Paz-Ares, A. D. Baron, T. Okusaka, T. Yoshino, H. H. Yoon, M. Das, D. Ferry, Y. Zhang, Y. Lin, P. Binder, A. Sashegyi, I. Chau; Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR1-binding monoclonal antibody ramucirumab; Annals of Oncology, December 2017:28(12):29320942.
OTHER:
1. Parks J., Mehrotra B. , Barnett B., Baron A., Venook A. "Sweet's Syndrome During G-CSF Therapy.' Annals ofInternal Medicine, 1992; 116:996-999.
2. Baron A., & Hollander, H. "Pseudomonas Aeruginosa Bronchopulmonary Infection in Late HIV Disease.' Presented at the 8 th International AIDS Conference, Amsterdam, July 1992. American Review ofRespiratory Diseases,
3. Ross H., Hart L, Swanson P., Rarick M., Figlin R., Jacobs A., McCune D., Rosenberg A., Baron A., Grove L., Thorn 1M. , Miller De, Sing, A, Drachman J., Rudin, C. "A Randomized Multicenter Study to Determine the Safety and Efficacy of the Immunoconjugate SGN*15 Plus Docetaxel for the Treatment of Non-Small Cell Lung Carcinoma". Lung Cancer, 2006;54, 69-77.
4. Burstein H., Keshaviah A. , Baron A., Hart R., Lambert-Falls R., Marcom P. , Gelman R. , Winer E. "Trastuzumab and Vinorelbine or Taxane Chemotherapy for HER-2+ Metastatic Breast Cancer: The TRAVIOTA Study." Cancer,
5. Steven P. Treon, Jacob D. Soumerai, Andrew R. Branagan, Zachary R. Hunter, Christopher J. Patterson, Leukothea Ioakimidis, Luis Chu, Paul Musto, Ari D. Baron, Johannes C. Nunnink, Joseph J. Kash, Terenig O. Terjanian, Paul M. Hyman, elena L. Nawfel, David J. Sharon, Nikhil C. Munshi, Kenneth C. Anderson. Lenalidomide and Rituximab in Waldenstrom's Macroglobulinemia. Clinical Cancer Res, January 1, 2009;15(1):355.
6. Maison-Blanche P, Dakhil S, Baron A, Rottey S, Millard F, Daugaard G, Machiels JP, Conkright W, Sharma S, Soetekouw PM, Yachnin J, Sengelov L, Van Veldhuizen P, Agarwala SS, Semiond D, Chadjaa M, Shen L, Wade JL. An open-label study to investigate the cardiac safety profile of cabazitaxel in patients with advanced solid 
tumors. Cancer Chemother Pharmacol, 2014 Jun; 73(6):1241-52.
“Sweet’s Syndrome During G-CSF Therapy.” Parks, J. Mehrotra, B., Barnett, B., Baron, A., Venook, A. Annals of Internal Medicine, 1992; 116:996-999
“Pseudomonas aeruginosa Bronchopulmonary Infection in Late HIV Disease.” Baron, A. and Hollander, H. Presented at the 8th International AIDS Conference, Amsterdam, July 1992. American Review of Respirator y Diseases, 1993; 148:992-6
“Ketoconazole Retains Activity in Advanced Prostate Cancer Patients Who Have Progressed Despite Flutamide Withdrawal.” Small, E.J., Baron, A.D., Fippin, L. Journal of Urology, 1997; 157:1204-07
“Simultaneous Anti-androgen withdrawal and Treatment with Ketoconazole in Patients with Advanced Hormone Refractory Prostate Cancer.” Small, E.S., Baron, A.D., Bok R. ASCO Abstract # 1117, 1997.
Cancer 1997; 80:1755-9
“Addition of Bevacizumab (rhuMab VEGF) to Bolus IFL in the First-Line Treatment of Patients With Metastatic
Colorectal Cancer : Results of a Randomized Phase III Trial.” Hurwitz, Fehrenbacher, Novotny, Car twright, Hainsworth, Heim, Berlin, Baron, Griffing, Holmgren, Ferrara, Fyfe, Rogers, Ross, Kabbinnavar New England Journal of Medicine 2004;350:2335-42.
“A Phase 2a Trial of Weekly Patupilone ( EPO 906) in Patients With Hormone- Refractory Prostate Cancer (HRPC.)” Hussain, Dipaola, Baron, Higano, Tchekmedyian, Miller, Rothermel ProcASCO 2004, Abstract# 4563.
Annals of Oncology 2009 20(3):492-497.
“Influence of Hepatic Dysfunction on Safety, Tolerability and Pharmacokinetics of PTK787/ZK 222584 in Patients with Unresectable Hepatocellular Carcinoma.” Koch, Baron, Roberts, Junker, Palacay-Ramona, Masson, Laurent, Kay, Wiedenmann, Cebon. ProcASCO 2005. Abstract # 4134.
“Traztuzumab and Vinorelbine or Taxane Chemotherapy for Her2+ Metastatic Breast Cancer : the TRAVIOTA Study.” H. Burstein, A. Keshaviah, A. Baron, R. Har t, R.
Lamber t-Falls, P. Marcom, R. Gelman, E. Winer ProcASCO 2006, Abstract # 650, and Cancer 2007; 110: 965-972.
“A Randomized Multicenter Study to Determine the Safety and Efficacy of the Immunoconjugate SGN-15 Plus
Docetaxel for the Treatment of Non-Small Cell Lung Carcinoma” H.Ross, L. Har t, P. Swanson, M. Rarick, R. Figlin, A. Jacobs, D. McCune, A. Rosenberg, A. Baron, L. Grove, M. Thorn, D. Miller, A. Sing, J. Drachman, C. Rudin Lung Cancer 2006; 54, 69-77
“Hepatocellular Carcinoma: Current and Evolving
Therapies” Gish, R and Baron, A., IDrugs 2008 11(3): 198-203
LECTURES
Prostate Cancer : Current Controversies and Advances, Medical Grand Rounds, California Pacific Medical Center, 4-97, Marin General, 12-97, Davies Medical Center, 1-98, Hawaiian Urologic Association, 1-98, John Muir Medical Center 7-98, San Francisco General Hospital 7-98, St. Mary’s Medical Center 1-00, Phoenix Urological Association, 2002, Tuscon VAMC 2002.
Lung Cancer : Update on Current Treatment, Kaiser Permanente, 12-97, Marin General Hospital 12-98, Good
Samaritan Hospital, San Jose,2003, Alvarado Hospital, San Diego 11-2006.
Hypercoagulability and Its Treatment, Medical Grand Rounds, California Pacific Medical Center 12-98, Davies
Medical Center 1-99.
Breast Cancer Prevention, Medical Grand Rounds, St. Joseph’s Medical Center, Burbank, California 1-99.
Targeted Therapy in Colorectal Cancer, Medical Grand Rounds, CPMC; Burbank; Portland; Seattle; Anchorage;
Medford; Racine; 8/03- present.